JP2017511327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511327A5 JP2017511327A5 JP2016560336A JP2016560336A JP2017511327A5 JP 2017511327 A5 JP2017511327 A5 JP 2017511327A5 JP 2016560336 A JP2016560336 A JP 2016560336A JP 2016560336 A JP2016560336 A JP 2016560336A JP 2017511327 A5 JP2017511327 A5 JP 2017511327A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- related antigen
- administration
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1405921.6A GB201405921D0 (en) | 2014-04-02 | 2014-04-02 | Novel methods for inducing an immune response |
| GB1405921.6 | 2014-04-02 | ||
| PCT/EP2015/057423 WO2015150567A1 (en) | 2014-04-02 | 2015-04-02 | Novel methods for inducing an immune response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511327A JP2017511327A (ja) | 2017-04-20 |
| JP2017511327A5 true JP2017511327A5 (enExample) | 2018-05-17 |
| JP6655549B2 JP6655549B2 (ja) | 2020-02-26 |
Family
ID=50737873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559965A Active JP6645982B2 (ja) | 2014-04-02 | 2015-04-02 | 免疫応答を誘導するための新規の方法 |
| JP2016560336A Expired - Fee Related JP6655549B2 (ja) | 2014-04-02 | 2015-04-02 | 免疫応答を誘導するための新規方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559965A Active JP6645982B2 (ja) | 2014-04-02 | 2015-04-02 | 免疫応答を誘導するための新規の方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10688168B2 (enExample) |
| EP (2) | EP3125930B1 (enExample) |
| JP (2) | JP6645982B2 (enExample) |
| KR (2) | KR102762440B1 (enExample) |
| CN (2) | CN106456739A (enExample) |
| AR (1) | AR099960A1 (enExample) |
| AU (1) | AU2015239025B2 (enExample) |
| BE (1) | BE1022355B1 (enExample) |
| BR (2) | BR112016022463A2 (enExample) |
| CA (2) | CA2943711A1 (enExample) |
| EA (1) | EA037405B1 (enExample) |
| ES (2) | ES2961840T3 (enExample) |
| GB (1) | GB201405921D0 (enExample) |
| IL (1) | IL247493B (enExample) |
| MX (3) | MX2016012982A (enExample) |
| SG (1) | SG11201607086QA (enExample) |
| WO (2) | WO2015150568A1 (enExample) |
| ZA (1) | ZA201605955B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| GB201621686D0 (en) * | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| GB2600653B (en) | 2017-05-30 | 2022-11-02 | Glaxosmithkline Biologicals Sa | Novel methods |
| BR112020010790A2 (pt) | 2017-12-01 | 2020-11-10 | Glaxosmithkline Biologicals S.A. | purificação da saponina |
| WO2020245207A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
| BR112022017852A2 (pt) | 2020-03-09 | 2022-11-01 | Dynavax Tech Corp | Vacinas para herpes zoster compreendendo um agonista de tlr9 |
| CN112198318B (zh) * | 2020-07-15 | 2021-07-20 | 南京岚煜生物科技有限公司 | 抗体标准品赋值和抗体检测试剂最低检出限确定的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US152200A (en) * | 1874-06-16 | Improvement in garters | ||
| US1002607A (en) * | 1905-08-28 | 1911-09-05 | John Willard Taylor | Paper pulley. |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| AU2003285932A1 (en) | 2002-10-23 | 2004-05-13 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| EA016648B1 (ru) | 2004-10-14 | 2012-06-29 | Круселл Холланд Б.В. | Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии |
| DK2457926T3 (da) * | 2005-04-29 | 2015-01-05 | Glaxosmithkline Biolog Sa | Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| US9297803B2 (en) * | 2006-11-01 | 2016-03-29 | Immport Therapeutics, Inc. | Compositions and methods for immunodominant antigens |
| PL2137210T3 (pl) * | 2007-03-02 | 2017-06-30 | Glaxosmithkline Biologicals Sa | Nowy sposób i kompozycje |
| PE20090146A1 (es) * | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
| CA2731549C (en) * | 2008-07-25 | 2018-07-17 | Glaxo Group Limited | Compositions and methods for treating tuberculosis |
| AU2009273130B2 (en) * | 2008-07-25 | 2014-10-16 | Glaxo Group Limited | Novel compositions and methods |
| AU2009273132B2 (en) * | 2008-07-25 | 2015-09-03 | Glaxo Group Limited | The tuberculosis Rv2386c protein, compositions and uses thereof |
| BR112012018669A2 (pt) * | 2010-01-27 | 2017-09-05 | Glaxosmithkline Biologicals Sa | Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo. |
| CN106822883A (zh) * | 2010-12-14 | 2017-06-13 | 葛兰素史密丝克莱恩生物有限公司 | 分枝杆菌抗原组合物 |
| WO2015126930A2 (en) * | 2014-02-18 | 2015-08-27 | Stc.Unm | Booster drug therapy for mycobacterium infections |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| US10004793B2 (en) * | 2014-04-24 | 2018-06-26 | Statens Serum Institut | M.tuberculosis vaccines |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
-
2014
- 2014-04-02 GB GBGB1405921.6A patent/GB201405921D0/en not_active Ceased
-
2015
- 2015-04-02 CN CN201580030331.2A patent/CN106456739A/zh active Pending
- 2015-04-02 MX MX2016012982A patent/MX2016012982A/es unknown
- 2015-04-02 JP JP2016559965A patent/JP6645982B2/ja active Active
- 2015-04-02 JP JP2016560336A patent/JP6655549B2/ja not_active Expired - Fee Related
- 2015-04-02 US US15/300,852 patent/US10688168B2/en active Active
- 2015-04-02 KR KR1020237017095A patent/KR102762440B1/ko active Active
- 2015-04-02 BR BR112016022463A patent/BR112016022463A2/pt not_active Application Discontinuation
- 2015-04-02 EP EP15713531.0A patent/EP3125930B1/en active Active
- 2015-04-02 EP EP15713532.8A patent/EP3125929B8/en active Active
- 2015-04-02 CA CA2943711A patent/CA2943711A1/en not_active Abandoned
- 2015-04-02 CN CN201580016665.4A patent/CN106456738B/zh active Active
- 2015-04-02 BR BR112016022787-5A patent/BR112016022787A2/pt not_active Application Discontinuation
- 2015-04-02 IL IL247493A patent/IL247493B/en unknown
- 2015-04-02 EA EA201691638A patent/EA037405B1/ru not_active IP Right Cessation
- 2015-04-02 BE BE2015/5209A patent/BE1022355B1/fr not_active IP Right Cessation
- 2015-04-02 CA CA2943007A patent/CA2943007C/en active Active
- 2015-04-02 US US15/300,338 patent/US10624961B2/en active Active
- 2015-04-02 ES ES15713532T patent/ES2961840T3/es active Active
- 2015-04-02 MX MX2016012932A patent/MX2016012932A/es unknown
- 2015-04-02 WO PCT/EP2015/057424 patent/WO2015150568A1/en not_active Ceased
- 2015-04-02 AU AU2015239025A patent/AU2015239025B2/en active Active
- 2015-04-02 SG SG11201607086QA patent/SG11201607086QA/en unknown
- 2015-04-02 ES ES15713531T patent/ES2853773T3/es active Active
- 2015-04-02 WO PCT/EP2015/057423 patent/WO2015150567A1/en not_active Ceased
- 2015-04-02 KR KR1020167029523A patent/KR20160132115A/ko not_active Ceased
- 2015-04-06 AR ARP150101025A patent/AR099960A1/es unknown
-
2016
- 2016-08-26 ZA ZA2016/05955A patent/ZA201605955B/en unknown
- 2016-09-30 MX MX2022013912A patent/MX2022013912A/es unknown
-
2020
- 2020-03-11 US US16/815,635 patent/US11951161B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511327A5 (enExample) | ||
| Akache et al. | Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice | |
| JP2017511324A5 (enExample) | ||
| WO2006060710A3 (en) | Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents | |
| JP2008539187A5 (enExample) | ||
| JP2018500322A5 (enExample) | ||
| BRPI0412444B1 (pt) | fração de quil a com baixa toxidez e seu uso | |
| JP2020528911A5 (enExample) | ||
| Lowell et al. | Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain | |
| TWI630915B (zh) | 無細胞百日咳疫苗 | |
| JP2015500827A5 (enExample) | ||
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| EP3125930B1 (en) | Novel methods for inducing an immune response | |
| JP2015524802A5 (enExample) | ||
| RU2015100889A (ru) | Вакцины для менингококка серогруппы х | |
| JP2021514387A5 (enExample) | ||
| CN110621339A (zh) | 疫苗接种 | |
| JP2015529677A5 (enExample) | ||
| IL276661B2 (en) | Immunogenic preparation containing staphylococcal antigens | |
| JP2018532782A5 (enExample) | ||
| Baz et al. | Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice | |
| WO2005074460A3 (en) | Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods | |
| Faingezicht et al. | Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine | |
| US11771757B2 (en) | Compositions and methods of manufacturing trivalent filovirus vaccines | |
| Sisteré-Oró et al. | Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate |